EMA recommends approval of letermovir for CMV in stem cell transplant recipients

European Medicines Agency recommends marketing authorisation for letermovir to prevent cytomegalovirus reactivation in stem cell transplant patients.
European Medicines Agency recommends marketing authorisation for letermovir to prevent cytomegalovirus reactivation in stem cell transplant patients.